key: cord-0986425-iead6qn9 authors: Saleh, Amani A.; Saad, Mohamed A.; Ryan, Islam; Amin, Magdy; Shindy, Mohamed I.; Hassan, Wael A.; Samir, Mahmoud; Khattab, Ayman A.; Abdelgayed, Sherein S.; Seadawy, Mohamed G.; Fahmy, Hossam M.; Amer, Khaled title: Safety and Immunogenicity Evaluation of Inactivated whole-virus-SARS-COV-2 As Emerging Vaccine Development In Egypt date: 2021-03-02 journal: bioRxiv DOI: 10.1101/2021.03.01.433130 sha: 19727b40decc8dc6312aaf4ab5dff92975d48505 doc_id: 986425 cord_uid: iead6qn9 The current worldwide pandemic COVID-19 is causing severe human health problems, with high numbers of mortality rates and huge economic burdens that require an urgent demand for safe, and effective and vaccine development. Our study was the first trail to development and evaluation of safety and immune response to inactivated whole SARS-COV-2 virus vaccine adjuvanted with aluminium hydroxide. We used characterized SARS-COV-2 strain, severe acute respiratory syndrome coronavirus 2 isolates (SARS-CoV-2/human/EGY/Egy-SERVAC/2020) with accession numbers; MT981440; MT981439; MT981441; MT974071; MT974069 and MW250352 at GenBank that isolated from Egyptian patients SARS-CoV-2-positive. Development of the vaccine was carried out in a BSL - 3 facilities and the immunogenicity was determined in mice at two doses (55µg and 100µg per dose). All vaccinated mice were received a booster dose 14 days post first immunization. Our results demonstrated distinct cytopathic effect on the vero cell monolayers induced through SARS-COV-2 propagation and the viral particles were identified as Coronaviridae by transmission electron microscopy. SARS-CoV-2 was identified by RT-PCR performed on the cell culture. Immunogenicity of the developed vaccine indicated the high antigen-binding and neutralizing antibody titers, regardless the dose concentration, with excellent safety profiles.However, no deaths or clinical symptoms in mice groups. The efficacy of the inactivated vaccine formulation was tested by wild virus challenge the vaccinated mice and detection of viral replication in lung tissues. Vaccinated mice recorded complete protection from challenge infection three weeks post second dose. SARS-COV-2 replication was not observed in the lungs of mice following SARS-CoV-2 challenge, regardless of the level of serum neutralizing antibodies. This finding will support the future trials for evaluation an applicable SARS-CoV-2 vaccine candidate. Coronavirus disease 2019 (COVID-19) is an emerging respiratory infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that had infected more than 16 million individuals and caused more than 656 000 deaths worldwide. A safe and effective vaccine against COVID-19 is urgently isolation of the virus from Egyptian patients followed by propagation, characterization and virus inactivation was conducted. In vitro neutralization was performed in mice as efficacy and immunogenicity were tested for preclinical evaluation of the inactivated vaccine candidate for further clinical trial approach. Nasopharyngeal and oropharyngeal swabs were collected in 5 ml viral transport media from six COVID-19 patients with age >45 years, whom were positively diagnosed using rRT-PCR. Swabs were transferred to Egypt Center for Research and Regenerative Medicine (ECRRM) BSL-3 laboratory and stored at 4 o C for immediate virus isolation. The approval of the ethics institutional review board (IRB) of Ministry of Defense, written informed consent was obtained from the participants. Using the precautions that adhered to or exceeded the requirements by WHO [11] , all experiments with suspected samples, infected cells, and infected fluids were performed in ECRRM Biosafety Level 3 laboratory and were conducted under appropriate conditions. Virus isolation was applied on Vero cell line of kidney epithelial cells derived from against complete SRAS-CoV-2 genome sequences retrieved from the GISAID website. All of the strains were isolated from Vero cells, which have been certified by WHO for vaccine production. Vero cells monolayer, were infected via the swabs of patients to prevent possible mutations during viral culture and isolation. Infected Vero cells were scraped from the flask, pelleted, and cell pellet was rinsed with 0.1M phosphate buffer (Sigma Aldrich, Germany). Cell suspensions collected from inoculated VERO Cell monolayers were first fixed with 2% Formaldehyde in phosphate buffered saline for 1h before ultracentrifugation (1h, 25,000 rpm), loading sample on carbon coating grid stained with 2% phosphor-tungestic acid for 30 seconds then examined. Bar:100nm. The 50% tissue culture infectious dose (TCID 50 ) per ml was determined in Vero cell monolayers on 24 and 96-well plates. Serial dilutions of virus samples were incubated at 37 o C for 4 days and subsequently examined for cytopathic effect (CPE) in infected cells. TCID 50 assay was performed according to [13] . The infectious titer was calculated using an in-house method adapted by Spearman and Kärber and expressed in TCID50 units [14] . For vaccine preparation, the virus was propagated in Vero cells with a dilution of 1:100 (v:v) of the SARS-CoV-2 virus in serum-free medium. The cells were incubated at 37 0 C for 72h. At three days post infection, when the cytopathic effect (CPE) was visible, the virus was harvested by collecting cell supernatants. The infectious titer of the virus was determined using a 50% cell culture infectious dose as described above. Vaccine purification was then performed with low-speed centrifugation (1000 rpm) to clarify the cell harvest followed by filtration. SARS-CoV-2 was inactivated with β -propiolactone at 2-8°C for 24-32 hours [15,16]. The final bulk was prepared as a liquid formulation containing 55 μg, or 100 μg total protein with aluminium hydroxide (Alhydrogel® CRODA health care Corp.) as adjuvant (0·45 mg/mL) per 0·5 ml. Effective inactivation of the virus was validated by inoculations of vero monolayers in 75 cm2 flasks with ten ml of inactivated virus, and then cultured at 36 ± 1°C for 4 days. No CPE was observed for three passages, in addition, Serum samples were heat-inactivated for 30 minutes at 56°C and serially diluted with cell culture medium in twofold dilution. The serum dilutions were mixed at a ratio of 1:1 with a SARS-CoV-2 virus stock suspension adjusted to 100 TCID 50 /ml, incubated for 1h at 37°C in a humidified atmosphere with 5% CO2 and transferred (eight replicates per dilution) to a 96-well tissue culture plate seeded with a Vero cells. The plates were incubated for 5 days at 37•C in a CO 2-incubator, before the cultures were inspected under a light microscope for the presence of a cytopathic effect (CPE) caused by SARS-CoV2, i.e. cell rounding and detachment. Neutralizing antibody titers were expressed as the reciprocal of the last dilution of serum that completely inhibited virus-induced CPE. Neutralizing antibody titers, lung virus titers, histopathologic lesion score and eosinophilic infiltration scores were averaged for each group of mice. Comparisons were conducted using parametric and nonparametric statistics as indicated Isolation and propagation SARS-COV2 virus for vaccine candidate development: A primary virus seed was generated from a human isolate by ten passages on vero cells. Distinct CPE in cells monolayer infected by SARS-CoV-2 was detected following an incubation period of 2-3days post cells infection (Fig.1) indicated that the virus grow well on Vero cells, so it was reflected that this was doubtless the optimal cell matrix for rapid vaccine development. This primary seed was further amplified to generate a seed virus bank, a working virus bank and a production virus bank. The production virus was then used to infect serum protein free vero cell cultures resulted in generation of high viral titres (10 7.5 TCID 50 /ml). Titration of the virus isolate revealed gradual increase in the virus titer through the successive passages (Fig.2) . The virus titer was 5 log10 TCID50 at the 4th passage and reached 6.5 log10 TCID50 by the 8th passage. At the final passage, the virus titer reached 7.5 log10 TCID50. The harvested virus containing supernatant was inactivated by β -propiolactone treatment at 2-8°C for 24. Inactivation was confirmed by three passages into Vero An electron micrograph of the purified inactivated virus showed virion particles belonging to the Coronaviridae Family were observed. Negatively stained electron microscopy image visualized oval viral particles with spikes having diameters of approximately 100 nm (Fig. 3) confirmed that virus particles being demonstrated to present well defined spikes on the virus membrane. No mortality or morbidity was observed in mice inoculated intraperitoneally with repeated doses of the vaccine and adjuvant. Moreover the experiment revealed that the inactivation steps were independently capable of inactivating this titre with a large margin of safety (Fig.4&5) . Mice were monitored daily post challenge for morbidity (weight) and mortality. No clinical signs were observed in vaccinated groups compared with unchallenged control group. Unvaccinated group showed rough hair with arched back 3 days post challenge. Candidate vaccine was highly efficacious in mice at the two dosage levels. The challenge virus replicated to titers 10 2.5 TCID 50 /ml and 10 5.4 TCID 50 in vero cell culture infected with homogenized lung tissues from mice at 3 and 7 days post infection, respectively. Replication of the challenge virus was not detected by Real-time PCR the lungs tissues of mice that received the vaccine and by absence of CPE in cell culture monolayer (Fig.6) . Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Key steps in vaccine development Fifteenth Laboratory biosafety guidance related to coronavirus disease (COVID-19) Isolation and characterization of bat SARS-like coronavirus that uses the ACE2 receptor A novel coronavirus associated with severe acute respiratory syndrome Determination of 50% endpoint titer using a simple formula Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV The authors have declared no conflict of interest References:1. World Health Organization. WHO coronavirus disease dashboard. Accessed July 30, 2020.